Novos suit, filed Feb
This isn't just another immune supplement stacked with vitamin C and wishful thinking
Shyamakant Giri, Chief Executive Officer of Gland Pharma, expressed optimism about the company's trajectory: "With the current momentum, we anticipate robust growth in the upcoming quarters." As Gland Pharma executes this expansion plan, it aims to strengthen its position in the injectable pharmaceuticals market and capitalize on the growing demand for GLP-1 therapies
The addition of lixisenatide to standard therapy did not significantly alter the rates of CV events or hospitalizations in high-risk patients, although it did result in modest but significant reductions in A1c, weight, and systolic BP compared to standard therapy
For Section 5, the search strategy prioritized studies addressing molecular and biochemical mechanisms associated with plant-derived compounds in Solenopsis spp
doi: 10.3389/fpain.2025.1593908